US 7,070,968 B2Granted

DNA damaging agents in combination with tyrosine kinase inhibitors

AssigneesArch Development Corporation, Dana-Farber Cancer Institute, Inc.

InventorsDonald Kufe, Ralph R. Weichselbaum

Life of this patent

Estimating the term…

Abstract

The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.

Claims25

Dependent claims

A method of inhibiting an undesirable cell comprising contacting said cell with a low molecular weight inhibitor of a tyrosine kinase and a DNA-damaging agent.

Dependencies are inferred from the claim text.

Facts

Application: 10/375,684Filed 24 Feb 2003 · continuation
Priority: 19 Aug 1994
Published: US 2004/0077087 A122 Apr 2004
Granted: 4 Jul 2006
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61N 5/10
Radiation therapy: x-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
A61K 31/365
Having oxygen as the only ring hetero atom, e.g. fungichromin: lactones
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/70
Medicinal preparations containing organic active ingredients: carbohydrates; Sugars; Derivatives thereof

Family

Application08/309,315Parent of this continuation · filed 19 Aug 1994
US 2004/0077087 A1Pre-grant publication · published 22 Apr 2004
US 6,524,832 B1Parent of this continuation
US 7,070,968 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results